share_log

TC BioPharm | 8-K: Current report

TC BioPharm | 8-K: Current report

TC BioPharm | 8-K：重大事件
SEC announcement ·  03/12 07:32
Moomoo AI 已提取核心訊息
On March 8, 2024, TC BioPharm announced significant corporate developments involving its CEO, Bryan Kobel. Kobel agreed to defer $66,000 in accrued pension benefits for nine months and convert $24,760 of these benefits into 476,153 ordinary shares of the company. The conversion rate was based on the closing price of TC BioPharm's American Depositary Shares (ADSs) on the Nasdaq Capital Market as of March 7, 2024, adjusted by the ADS ratio. Additionally, the company's board of directors approved an options grant for Kobel to purchase 153,000 ADSs, representing 3,060,000 ordinary shares, at an exercise price of $2.00 per ADS, which is above the closing price from the previous day. These options, issued under the company's 2021 Shares Option Scheme, vested immediately. This corporate action follows the company's guidelines as outlined in their Annual Report on 20-F for the fiscal year ended December 31, 2022.
On March 8, 2024, TC BioPharm announced significant corporate developments involving its CEO, Bryan Kobel. Kobel agreed to defer $66,000 in accrued pension benefits for nine months and convert $24,760 of these benefits into 476,153 ordinary shares of the company. The conversion rate was based on the closing price of TC BioPharm's American Depositary Shares (ADSs) on the Nasdaq Capital Market as of March 7, 2024, adjusted by the ADS ratio. Additionally, the company's board of directors approved an options grant for Kobel to purchase 153,000 ADSs, representing 3,060,000 ordinary shares, at an exercise price of $2.00 per ADS, which is above the closing price from the previous day. These options, issued under the company's 2021 Shares Option Scheme, vested immediately. This corporate action follows the company's guidelines as outlined in their Annual Report on 20-F for the fiscal year ended December 31, 2022.
2024年3月8日，TC BioPharm宣佈了涉及其首席執行官布萊恩·科貝爾的重大公司發展。科貝爾同意將66,000美元的應計養老金福利推遲九個月，並將這些福利中的24,760美元轉換爲公司的476,153股普通股。轉換率基於TC BioPharm截至2024年3月7日在納斯達克資本市場上的美國存托股票（ADS）的收盤價，經ADS比率調整。此外，公司董事會批准了Kobel的期權授權，以每股ADS的行使價爲2.00美元，高於前一天的收盤價，購買15.3萬股美國存託憑證，相當於306萬股普通股。根據公司2021年股票期權計劃發行的這些期權立即歸屬。該公司行動遵循了公司在截至2022年12月31日財年的20-F年度報告中概述的指導方針。
2024年3月8日，TC BioPharm宣佈了涉及其首席執行官布萊恩·科貝爾的重大公司發展。科貝爾同意將66,000美元的應計養老金福利推遲九個月，並將這些福利中的24,760美元轉換爲公司的476,153股普通股。轉換率基於TC BioPharm截至2024年3月7日在納斯達克資本市場上的美國存托股票（ADS）的收盤價，經ADS比率調整。此外，公司董事會批准了Kobel的期權授權，以每股ADS的行使價爲2.00美元，高於前一天的收盤價，購買15.3萬股美國存託憑證，相當於306萬股普通股。根據公司2021年股票期權計劃發行的這些期權立即歸屬。該公司行動遵循了公司在截至2022年12月31日財年的20-F年度報告中概述的指導方針。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息